Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
212 studies found for:    Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" (212 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Unknown  Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Myelogenous Leukemia, Chronic, Chronic Phase
Intervention:
2 Recruiting Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Medication Adherence
Interventions: Behavioral: Adherence-encouraging interventions - Group meeting;   Behavioral: Adherence-encouraging interventions - Individual meetings;   Behavioral: Adherence-encouraging interventions - Monthly phone calls
3 Recruiting Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Conditions: Leukemia;   Leukemia, Myeloid;   Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Philadelphia Chromosome;   Bone Marrow Diseases;   Hematologic Diseases
Interventions: Drug: Imatinib;   Drug: Radotinib
4 Recruiting Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: Echo, exercise echo, and if indicated, right heart catheter
5 Recruiting Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
Condition: Chronic Myeloid Leukemia
Intervention: Behavioral: Dasatinib discontinuation
6 Recruiting Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention: Drug: P1101
7 Recruiting Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Condition: Chronic Myelogenous Leukemia
Intervention: Other: Chart Review
8 Recruiting Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Conditions: Chronic Phase Philadelphia Positive;   BCR-ABL Positive;   Chronic Myeloid Leukaemia
Intervention:
9 Recruiting TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib/Nilotinib
10 Unknown  A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
Condition: Chronic Myeloid Leukemia
Intervention: Drug: dasatinib
11 Recruiting LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients
Condition: Chronic Myeloid Leukemia
Intervention: Other: QoL Survey Booklet
12 Not yet recruiting Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Conditions: Chronic Phase Chronic Myeloid Leukemia;   Accelerated Phase Chronic Myeloid Leukemia;   Blastic Phase Chronic Myeloid Leukemia;   Philadelphia Positive Acute Lymphoblastic Leukemia;   Resistant to Tyrosine Kinase Inhibitor Therapy
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
13 Recruiting Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Condition: Chronic Myeloid Leukemia
Intervention:
14 Not yet recruiting RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
Condition: Chronic Myeloid Leukemia
Interventions: Drug: RAD001;   Drug: Imatinib
15 Recruiting Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Imatinib
16 Recruiting Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib
17 Available Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Condition: Chronic Myeloid Leukemia
Intervention: Drug: bosutinib
18 Not yet recruiting Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: BL-8040
19 Recruiting A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Omacetaxine mepesuccinate
20 Recruiting Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Condition: Philidelphia Positive Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years